Literature DB >> 10489228

Association of hyperphosphataemia with haemodynamic disturbances in end-stage renal disease.

S J Marchais1, F Metivier, A P Guerin, G M London.   

Abstract

BACKGROUND: Because recent data demonstrated that the shortened survival and excess cardiovascular death of end-stage renal disease (ESRD) patients are predicted by hyperphosphataemia, we examined the haemodynamic alterations associated with high serum phosphorus levels in ESRD patients on haemodialysis.
METHODS: Sixty-six ESRD patients were studied. Patients were separated arbitrarily into two groups, i.e. with predialysis serum phosphate <2 mmol/l ('normal' phosphate) and, serum phosphate >2 mmol/l ('high' phosphate). Cardiac and arterial function and structure were analysed by computer-assisted ultrasonography.
RESULTS: Hyperphosphataemic patients were characterized by higher diastolic and mean blood pressures (P<0.05), and higher cardiac index (P<0.001) caused by an increased stroke index (P<0.05) and higher heart rate (P<0.01). The cardiac work index was significantly increased in patients with higher phosphate levels (P<0.01). Hyperphosphataemic patients tended to have a higher common carotid artery diameter (P=0.07), but similar carotid artery intima-media thickness, and lower carotid wall-to-lumen ratio (P<0.05) than patients with 'normal' serum phosphorus. As a result of lower wall-to-lumen ratio in the presence of higher mean blood pressure, the carotid tensile stress was higher in hyperphosphataemic ESRD patients (P<0.05).
CONCLUSION: These findings suggest that, in stable ESRD patients, hyperphosphataemia is associated with increased BP, hyperkinetic circulation, increased cardiac work, and high arterial tensile stress. These haemodynamic abnormalities could favour the development of cardiovascular complications and contribute to high cardiovascular morbidity and mortality.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10489228     DOI: 10.1093/ndt/14.9.2178

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  17 in total

Review 1.  Calciphylaxis and vascular calcification: a continuum of extra-skeletal osteogenesis.

Authors:  Sharon M Moe; Neal X Chen
Journal:  Pediatr Nephrol       Date:  2003-10       Impact factor: 3.714

2.  Blood pressure control in pediatric hemodialysis: the Midwest Pediatric Nephrology Consortium Study.

Authors:  Rene' G VanDeVoorde; Gina M Barletta; Deepa H Chand; Ian G Dresner; Jerome Lane; Jeffrey Leiser; Jen-Jar Lin; Cynthia G Pan; Hiren Patel; Rudolph P Valentini; Mark M Mitsnefes
Journal:  Pediatr Nephrol       Date:  2006-11-07       Impact factor: 3.714

3.  Osteoporosis and cardiovascular disease: lessons from chronic kidney disease.

Authors:  Keith A Hruska; Suresh Mathew; Richard Lund
Journal:  Clin Cases Miner Bone Metab       Date:  2008-01

Review 4.  Mineral metabolism abnormalities and vitamin D receptor activation in cardiorenal syndromes.

Authors:  Claudio Ronco; Mario Cozzolino
Journal:  Heart Fail Rev       Date:  2012-03       Impact factor: 4.214

5.  Absorption and excretion of colestilan in healthy subjects.

Authors:  Koji Takei; Sian Dale; Heather Charles; Akira Sasaki; Shigekazu Nakajima
Journal:  Clin Pharmacokinet       Date:  2010       Impact factor: 6.447

Review 6.  Hyperphosphatemia of chronic kidney disease.

Authors:  Keith A Hruska; Suresh Mathew; Richard Lund; Ping Qiu; Raymond Pratt
Journal:  Kidney Int       Date:  2008-04-30       Impact factor: 10.612

7.  Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: the ACHIEVE study results.

Authors:  Steven Fishbane; Warren B Shapiro; Dalila B Corry; Steven L Vicks; Michael Roppolo; Kenneth Rappaport; Xiang Ling; William G Goodman; Stewart Turner; Chaim Charytan
Journal:  Clin J Am Soc Nephrol       Date:  2008-11       Impact factor: 8.237

Review 8.  Left Ventricular Hypertrophy in Chronic Kidney Disease Patients: From Pathophysiology to Treatment.

Authors:  Luca Di Lullo; Antonio Gorini; Domenico Russo; Alberto Santoboni; Claudio Ronco
Journal:  Cardiorenal Med       Date:  2015-07-15       Impact factor: 2.041

9.  Association of calcium-phosphorus product with blood pressure in dialysis.

Authors:  Ziad M Ashkar
Journal:  J Clin Hypertens (Greenwich)       Date:  2010-02-01       Impact factor: 3.738

Review 10.  Cardiovascular risk factors in chronic kidney disease: does phosphate qualify?

Authors:  Keith Hruska; Suresh Mathew; Richard Lund; Yifu Fang; Toshifumi Sugatani
Journal:  Kidney Int Suppl       Date:  2011-02-23       Impact factor: 10.545

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.